PULSE BIOSCIENCES INC (PLSE)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PLSE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PLSE | Co-Chairman of the Board of Directors, Chief Executive Officer and President; Chief Executive Officer, President & Co-Chairman of the Board of Directors | 68 | [] | ["Audit Committee","Corporate Governance and Nominating Committee","Strategic Advisory Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EW | CEO, Pulse Biosciences, Inc., Managing Partner and COO, SV Health Investors LLC; Chair of the Compensation and Governance Committee | 68 | ["Over 40 years in the medical technology industry", "Extensive global executive experience", "Experience in strategy and innovation", "Operations management", "Human capital resources", "Marketing and communications", "Corporate strategy and corporate governance", "Experience in serving on other boards and chairmanships"] | ["Compensation and Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Paul A. LaViolette is our Co-Chairman of the Board of Directors and our current Chief Executive Officer. He was appointed as our President and Chief Executive Officer as of January 9, 2025. He did not receive any employment compensation from us during fiscal years 2024, 2023 and 2022. His current annual base salary is $725,000. Presently, he is eligible for an annual target bonus equal to 70% of his annual base salary, subject to achievement of performance objectives. He is also eligible to participate in employee benefit plans maintained from time to time by us of general applicability to other senior executives. His employment agreement provided him the right to receive an option to purchase up to 1,500,000 shares of our common stock. If his employment is involuntary terminated within twelve months following a Company change of control, 100% of his unvested equity awards then outstanding will fully vest and become exercisable. If his employment is involuntarily terminated not in connection with a Company change of control, then the vesting of his outstanding equity awards that would normally vest over the following twelve-month period will immediately accelerate and fully vest prior to his termination. If we terminate his employment other than for cause, death, or disability or if he resigns for good reason, he is entitled to receive continuing payments of his then-current base salary for a period of three months following his termination of employment or for a period of twelve months if occurring within twelve months of a change of control, less applicable withholdings, and reimbursement of premiums to maintain group health insurance continuation benefits pursuant to COBRA for him and his respective dependents until the earlier of him or his eligible dependents becoming covered under similar plans, or the date upon which he ceases to be eligible for coverage under COBRA, or the twelve month anniversary of the termination of his employment. He has also entered into our standard inventions assignment, confidentiality and non-competition agreement and our standard indemnification agreement for officers and directors.